Oral Administration of Recombinant Adeno-associated Virus-mediated Bone Morphogenetic Protein-7 Suppresses CCl4-induced Hepatic Fibrosis in Mice  Zhi-Ming.

Slides:



Advertisements
Similar presentations
The BH3-Only Protein Bid Does Not Mediate Death-Receptor-Induced Liver Injury in Obstructive Cholestasis  Padmavathi devi Nalapareddy, Sven Schüngel,
Advertisements

Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Molecular Therapy - Methods & Clinical Development
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver  Wei Huang, Xianglan Liu,
Volume 85, Issue 3, Pages (March 2014)
Volume 131, Issue 3, Pages (September 2006)
Volume 131, Issue 1, Pages (July 2006)
Volume 16, Issue 10, Pages (October 2008)
Volume 16, Issue 8, Pages (August 2008)
TSG-6 Released from Intradermally Injected Mesenchymal Stem Cells Accelerates Wound Healing and Reduces Tissue Fibrosis in Murine Full-Thickness Skin.
Volume 129, Issue 1, Pages (July 2005)
Cytoglobin Overexpression Protects against Damage-Induced Fibrosis
Volume 146, Issue 5, Pages e1 (May 2014)
Volume 125, Issue 6, Pages (December 2003)
Volume 22, Issue 8, Pages (August 2014)
Volume 15, Issue 1, Pages (January 2007)
Volume 18, Issue 5, Pages (May 2010)
Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis  Jung-Yeon Kim, Hyun-Jin An, Woon-Hae.
Volume 9, Issue 2, Pages (February 2004)
Volume 25, Issue 11, Pages (November 2017)
Abrogation of the Antifibrotic Effects of Natural Killer Cells/Interferon-γ Contributes to Alcohol Acceleration of Liver Fibrosis  Won–Il Jeong, Ogyi.
Volume 22, Issue 3, Pages (March 2014)
Volume 18, Issue 9, Pages (September 2010)
A Dual AP-1 and SMAD Decoy ODN Suppresses Tissue Fibrosis and Scarring in Mice  Hong-Feng Yuan, Hong Huang, Xiang-Yun Li, Wei Guo, Wei Xing, Zhi-Ya Sun,
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver  Wei Huang, Xianglan Liu,
Molecular Therapy - Nucleic Acids
Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes  Shunsuke Iizuka, Fuminori Sakurai,
Volume 18, Issue 6, Pages (June 2010)
Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy  Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura 
TRPV4 ION Channel Is Associated with Scleroderma
Volume 16, Issue 8, Pages (August 2008)
Volume 15, Issue 6, Pages (June 2007)
Volume 18, Issue 11, Pages (November 2010)
Volume 18, Issue 2, Pages (February 2010)
Volume 18, Issue 9, Pages (September 2010)
Molecular Therapy - Methods & Clinical Development
Volume 24, Issue 2, Pages (February 2016)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Molecular Therapy - Nucleic Acids
Volume 12, Issue 6, Pages (December 2005)
Volume 23, Issue 10, Pages (October 2015)
Volume 13, Issue 1, Pages (January 2006)
Volume 19, Issue 10, Pages (October 2011)
Volume 19, Issue 7, Pages (July 2011)
Volume 17, Issue 12, Pages (December 2009)
Volume 25, Issue 3, Pages (March 2017)
Volume 19, Issue 6, Pages (June 2011)
Volume 18, Issue 8, Pages (August 2010)
Volume 18, Issue 3, Pages (March 2010)
Volume 17, Issue 1, Pages (January 2009)
Volume 20, Issue 3, Pages (March 2012)
Volume 20, Issue 6, Pages (June 2012)
Molecular Therapy - Nucleic Acids
miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice
Volume 18, Issue 12, Pages (December 2010)
Volume 18, Issue 6, Pages (June 2010)
Volume 18, Issue 6, Pages (June 2010)
MicroRNA-125b Promotes Hepatic Stellate Cell Activation and Liver Fibrosis by Activating RhoA Signaling  Kai You, Song-Yang Li, Jiao Gong, Jian-Hong Fang,
Volume 22, Issue 2, Pages (February 2014)
Volume 24, Issue 6, Pages (December 2016)
Volume 18, Issue 7, Pages (July 2010)
Volume 16, Issue 4, Pages (April 2008)
Volume 24, Issue 11, Pages (November 2016)
Jennifer Altomonte, Sabrina Marozin, Roland M Schmid, Oliver Ebert 
Volume 15, Issue 9, Pages (September 2007)
Volume 20, Issue 4, Pages (April 2012)
Volume 3, Issue 5, Pages (May 2001)
Volume 16, Issue 4, Pages (April 2008)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 10, Pages (October 2010)
Presentation transcript:

Oral Administration of Recombinant Adeno-associated Virus-mediated Bone Morphogenetic Protein-7 Suppresses CCl4-induced Hepatic Fibrosis in Mice  Zhi-Ming Hao, Min Cai, Yi-Fei Lv, Yan-Hua Huang, Hong-Hong Li  Molecular Therapy  Volume 20, Issue 11, Pages 2043-2051 (November 2012) DOI: 10.1038/mt.2012.148 Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 The oral administration of AAV–BMP-7 mediates the ectopic expression of BMP-7 in the GI tract and leads to elevated serum BMP-7 concentrations in mice. The in situ β-Gal staining of the intestine 3 days after the second oral administration of virus showed the ectopic expression of LacZ (blue) in the lamina propria and epithelia in mice that received (a) AAV-LacZ but not in mice that received (b) PBS. Likewise, the immunohistochemical staining of the intestine revealed ectopic BMP-7 expression in the mice that received (c) AAV–BMP-7 but not in the mice that received (d) PBS. Bars = 200 µm. (e) The serum BMP-7 concentrations were determined by ELISA 3 days after the second oral dose of 1 × 1010 vg AAV–BMP-7, AAV-LacZ or an equal volume of PBS. The error bars indicate SEM. (f) The mice were orally dosed twice, 3 days apart, with AAV–BMP-7 (1 × 1010 vg for the AAV–BMP-7/CCl4 group), AAV-LacZ (1 × 1010 vg for the AAV-LacZ/CCl4 group), or PBS (for the NC and CCl4 groups). Three days after the second dose, the mice were injected i.p. with CCl4 twice a week for 7 weeks (1 ml/kg BW for the AAV–BMP-7/CCl4, AAV-LacZ/CCl4 and CCl4 groups) or olive oil (for the NC group). The serum BMP-7 concentrations were determined after 7 weeks by ELISA. The error bars indicate SEM. AAV, adeno-associated virus; BMP-7, bone morphogenetic protein-7; CCl4, carbon tetrachloride; ELISA, enzyme-linked immunosorbant assay; i.p., intraperitoneal; IH, immunohistochemistry; NC, normal control; PBS, phosphate-buffered saline; SEM, standard error of the mean; vg, viral genome; β-Gal, β-Galactosidase. Molecular Therapy 2012 20, 2043-2051DOI: (10.1038/mt.2012.148) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 The oral administration of AAV–BMP-7 suppresses hepatic fibrosis in mice, as shown by Masson's trichrome staining, hepatic hydroxyproline content and serum HA concentration. The AAVs were administered, and fibrosis was induced as described the legend to Figure 1f. Representative figures of the Masson's trichrome-stained mouse livers from the (a) NC, (b) AAV–BMP-7/CCl4, (c) AAV-LacZ/CCl4, and (d) CCl4 groups. Bars = 200 µm. (e) The liver hydroxyproline content was determined by a biochemical assay. The hydroxyproline content is expressed as µg/mg wet liver weight. The error bars indicate SEM. (f) The serum hyaluronic acid concentration was determined by ELISA and is expressed as ng/ml serum. The error bars indicate SEM. AAV, adeno-associated virus; BMP-7, bone morphogenetic protein-7; CCl4, carbon tetrachloride; HA, hyaluronic acid; NC, normal control; SEM, standard error of the mean. Molecular Therapy 2012 20, 2043-2051DOI: (10.1038/mt.2012.148) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 The ectopic expression of BMP-7 reduces the expression of α-SMA in the livers of CCl4-treated mice. AAV was administered, and fibrosis was induced as described in the legend to Figure 1f. The fixed liver tissues were sectioned and were immunostained with anti-α-SMA antibody. Representative immunostained liver sections are shown for the (a) NC; (b) AAV–BMP-7/CCl4; (c) AAV-LacZ/CCl4; and (d) CCl4 groups. Bars = 200 µm. (e) The quantitative computer-assisted morphometric analysis of the immunostained activated HSCs (α-SMA–positive cells) in the four groups. The error bars indicate SEM. AAV, adeno-associated virus; BMP-7, bone morphogenetic protein-7; CCl4, carbon tetrachloride; NC, normal control; SEM, standard error of the mean. Molecular Therapy 2012 20, 2043-2051DOI: (10.1038/mt.2012.148) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 The ectopically expressed BMP-7 reduces the expression of hepatic desmin in CCl4-treated mice. The AAVs were administered, and fibrosis was induced as described in the legend to Figure 1f. The fixed liver tissues were sectioned and immunostained with an anti-desmin antibody. The immunostained liver sections are from the (a) NC; (b) AAV–BMP-7/CCl4; (c) AAV-LacZ/CCl4; and (d) CCl4 groups. (e) The immunostaining indicates that some of the desmin-positive cells are hepatocytes. Bars = 200 µm. (f) Quantitative computer-assisted morphometric analysis of the immunostained desmin-positive cells in the four groups. The error bars indicate SEM. AAV, adeno-associated virus; BMP-7, bone morphogenetic protein-7; CCl4, carbon tetrachloride; NC, normal control; SEM, standard error of the mean. Molecular Therapy 2012 20, 2043-2051DOI: (10.1038/mt.2012.148) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 The oral administration of AAV–BMP-7 promotes parenchymal cell proliferation but inhibits mesenchymal cell proliferation in the fibrotic mouse livers. The AAVs were administered, and fibrosis was induced as described in Figure 1f. The fixed liver tissues were sectioned and immunostained with an anti-PCNA antibody. The immunostained liver sections are shown from the (a) NC; (b) AAV–BMP-7/CCl4; (c) AAV-LacZ/CCl4; and (d) CCl4 groups. Bars = 200 µm. The PCNA LIs of the (e) mesenchymal and (f) parenchymal cells. The error bars indicate SEM. AAV, adeno-associated virus; BMP-7, bone morphogenetic protein-7; CCl4, carbon tetrachloride; LI, labeling index; NC, normal control; PCNA, proliferating cell nuclear antigen; SEM, standard error of the mean. Molecular Therapy 2012 20, 2043-2051DOI: (10.1038/mt.2012.148) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions